Lx TB PstS1Alternative Names: Lx TB PstS1 antigen; Lx-Bladder; Lx-Bladder antigen; PstS1
Latest Information Update: 15 Sep 2015
At a glance
- Originator Lionex
- Developer Axenoll
- Class Antigens; Antineoplastics
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bladder cancer
Most Recent Events
- 03 Feb 2010 Phase-I/II clinical trials in Bladder cancer in Switzerland (Parenteral)